Carboxylesterase 2 As a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2015 May 31

PMID 26025324

Citations 37

Authors

Michela Capello

Minhee Lee

Hong Wang

Ingrid Babel

Matthew H Katz

Jason B Fleming

Anirban Maitra

Huamin Wang

Weihua Tian

Ayumu Taguchi

Samir M Hanash

Affiliations

Soon will be listed here.

Abstract

Background: Serine hydrolases (SHs) are among the largest classes of enzymes in humans and play crucial role in many pathophysiological processes of cancer. We have undertaken a comprehensive proteomic analysis to assess the differential expression and cellular localization of SHs, which uncovered distinctive expression of Carboxylesterase 2 (CES2), the most efficient carboxyl esterase in activating the prodrug irinotecan into SN-38, in pancreatic ductal adenocarcinoma (PDAC). We therefore assessed the extent of heterogeneity in CES2 expression in PDAC and its potential relevance to irinotecan based therapy.

Methods: CES2 expression in PDAC and paired nontumor tissues was evaluated by immunohistochemistry. CES2 activity was assessed by monitoring the hydrolysis of the substrate p-NPA and correlated with irinotecan IC50 values by means of Pearson's correlation. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and CES2 expression in patients who underwent neoadjuvant FOLFIRINOX treatment. All statistical tests were two-sided.

Results: Statistically significant overexpression of CES2, both at the mRNA and protein levels, was observed in PDAC compared with paired nontumor tissue (P < .001), with 48 of 118 (40.7%) tumors exhibiting high CES2 expression. CES2 activity in 11 PDAC cell lines was inversely correlated with irinotecan IC50 values (R = -0.68, P = .02). High CES2 expression in tumor tissue was associated with longer overall survival in resectable and borderline resectable patients who underwent neoadjuvant FOLFIRINOX treatment (hazard ratio = 0.14, 95% confidence interval = 0.04 to 0.51, P = .02).

Conclusion: Our findings suggest that CES2 expression and activity, by mediating the intratumoral activation of irinotecan, is a contributor to FOLFIRINOX sensitivity in pancreatic cancer and CES2 assessment may define a subset of patients likely to respond to irinotecan based therapy.

Citing Articles

Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.

Chen Q, Hao Q, Yang Y, Li L, Li D, Zhao R Technol Cancer Res Treat. 2025; 24:15330338251319144.

PMID: 39912257 PMC: 11800256. DOI: 10.1177/15330338251319144.

Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma.

Kluz N, Kraj L, Chmiel P, Przybylkowski A, Wyrwicz L, Stec R Cancers (Basel). 2024; 16(23).

PMID: 39682132 PMC: 11640600. DOI: 10.3390/cancers16233945.

Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice.

Wang Y, Gan C, Beukers-Korver J, Rosing H, Li W, Wagenaar E Acta Pharmacol Sin. 2024; 46(3):777-793.

PMID: 39496863 PMC: 11845761. DOI: 10.1038/s41401-024-01407-4.

Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response.

An J, Kurilov R, Peccerella T, Bergmann F, Edderkaoui M, Lim A Transl Oncol. 2024; 49:102109.

PMID: 39217851 PMC: 11402625. DOI: 10.1016/j.tranon.2024.102109.

PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice.

Jung J, Schneider E, Zhang W, Song H, Zhang M, Chou W Sci Rep. 2024; 14(1):14175.

PMID: 38898077 PMC: 11187204. DOI: 10.1038/s41598-024-64186-2.

References

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

Von Hoff D, Goldstein D, Renschler M . Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med. 2014; 370(5):479-80. DOI: 10.1056/NEJMc1314761. View

Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D . FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2014; 14(10):1115-25. DOI: 10.1586/14737140.2014.957188. View

Khanna R, Morton C, Danks M, Potter P . Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res. 2000; 60(17):4725-8. View

Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum Y . Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19(5):1501-18. DOI: 10.1200/JCO.2001.19.5.1501. View

Wang H, Wang H, Zhang W, Fuller G . Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 2002; 12(1):95-107. PMC: 8095954. DOI: 10.1111/j.1750-3639.2002.tb00426.x. View

Del Rosso M, Fibbi G, Pucci M, DAlessio S, Rosso A, Magnelli L . Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis. 2002; 19(3):193-207. DOI: 10.1023/a:1015531321445. View

Xu G, Zhang W, Ma M, McLeod H . Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res. 2002; 8(8):2605-11. View

10.

Xu Y, Villalona-Calero M . Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002; 13(12):1841-51. DOI: 10.1093/annonc/mdf337. View

11.

Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr H . Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci. 2003; 77(1):19-34. DOI: 10.1093/toxsci/kfh016. View

12.

Jessani N, Humphrey M, McDonald W, Niessen S, Masuda K, Gangadharan B . Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci U S A. 2004; 101(38):13756-61. PMC: 518829. DOI: 10.1073/pnas.0404727101. View

13.

BEAUFAY H, Feytmans E, Thines-Sempoux D, Wibo M, Robbi M, Berthet J . Analytical study of microsomes and isolated subcellular membranes from rat liver. I. Biochemical methods. J Cell Biol. 1974; 61(1):188-200. PMC: 2109252. DOI: 10.1083/jcb.61.1.188. View

14.

Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K . Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51(16):4187-91. View

15.

Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y . A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992; 10(1):16-20. DOI: 10.1200/JCO.1992.10.1.16. View

16.

Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, NAKAO I . [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. Gan To Kagaku Ryoho. 1994; 21(7):1039-46. View

17.

Wagener D, Verdonk H, Dirix L, Catimel G, Siegenthaler P, Buitenhuis M . Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995; 6(2):129-32. DOI: 10.1093/oxfordjournals.annonc.a059107. View

18.

Satoh T, Hosokawa M . The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 1998; 38:257-88. DOI: 10.1146/annurev.pharmtox.38.1.257. View

19.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R . Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998; 352(9138):1407-12. DOI: 10.1016/S0140-6736(98)03085-2. View

20.

Cunningham D, Pyrhonen S, James R, Punt C, Hickish T, Heikkila R . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352(9138):1413-8. DOI: 10.1016/S0140-6736(98)02309-5. View